Zur Rose receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DocMorris AG (DOCM)
The DocMorris share price today is 10.26, view SIX DOCM stock exchange data. Track the latest DocMorris share price with real-time updates on DOCM stock performance including market cap, day range, 52-week range and dividend yield. Access DOCM charts, earnings dates and analyst estimates to support your investment decisions.
10.26
+0.36(+3.64%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.95
10.37
52 wk Range
3.92
11.25
DOCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.9510.37
52 wk Range
3.9211.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
DOCM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
11.04
Upside
+7.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
Zur Rose receives Investment Bank Analyst Rating Update- Investing.com
Pro
Why is DocMorris stock sliding today?- Investing.com
Zur Rose receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Zur Rose receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Zur Rose receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Zur Rose receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
5 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 11.04
(+7.64% Upside)
DocMorris AG Earnings Call Summary for Q2/2026
- DocMorris reported H1 2026 revenue growth of 13.4% in local currency, driven by 38.3% Rx revenue increase and 71% digital services jump.
- Adjusted EBITDA margin improved 350 basis points to -1.8%, though shares fell 6.02% to $9.05 despite raised guidance and strong results.
- Company raised 2026 revenue growth guidance to 9-13% from 3-12%; narrowed expected EBITDA loss to CHF 10-17.5M from CHF 10-25M.
- Management reaffirmed EBITDA breakeven target during 2026; AI-First strategy expected to deliver CHF 50M+ annual savings by end of 2027.
- Key risks include continued cash burn of $114M, negative profitability, and execution uncertainty around co-payment strategy for 2027.
Last Updated: 19-08-2026, 03:52 pm
Read Full TranscriptEarnings
Latest Release
19-08-2026
EPS / Forecast
-1.10 / --
Revenue / Forecast
295.2M / 286.05M
Compare DOCM to Peers and Sector
Metrics to compare | DOCM | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipDOCMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −3.0x | 11.6x | |
PEG Ratio | −0.07 | 0.03 | 0.03 | |
Price/Book | 1.4x | 1.4x | 1.5x | |
Price / LTM Sales | 0.4x | 0.6x | 0.9x | |
Upside (Analyst Target) | 2.9% | 10.5% | 22.4% | |
Fair Value Upside | Unlock | 14.2% | 12.6% | Unlock |
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma by DocMorris, and TeleClinic brands. The company was formerly known as Zur Rose Group AG and changed its name to DocMorris AG in May 2023. DocMorris AG was founded in 1993 and is headquartered in Frauenfeld, Switzerland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the DocMorris (DOCM) Share Price Today?
The DocMorris share price today is 10.26.
What is the current DocMorris (DOCM) share price and day range?
As of 26-08-2026, the DocMorris share price is 10.26, with a previous close of 9.90. The share price has ranged from 9.95 to 10.37 today, while the 52-week range spans from 3.92 to 11.25.
What Is the DocMorris Market Cap?
As of today, DocMorris market cap is 518.02M.
What Is the DocMorris (DOCM) Share Price Target?
The average 12-month share price target for DocMorris is 11.04, with a high estimate of 13.6 and a low estimate of 9.5. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +7.64% Upside potential.
What Is DocMorris's Earnings Per Share (TTM)?
The DocMorris EPS (TTM) is -2.61.
When Is the Next DocMorris Earnings Date?
DocMorris will release its next earnings report on 15-10-2026.
From a Technical Analysis Perspective, Is DOCM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does DocMorris Trade On?
DocMorris is listed and trades on the Switzerland Stock Exchange.
What Is the Stock Symbol for DocMorris?
The stock symbol for DocMorris is "DOCM."
How Many Times Has DocMorris Stock Split?
DocMorris has split 2 times.
How Many Employees Does DocMorris Have?
DocMorris has 1337 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.